CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
🤖 D.R.A.F.T. Summary
CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health
Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease TORONTO, May 06, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin Canada, a wholly owned subsidiary of Kyowa Kirin Inc., is pleased to announce that CRYSVITA® (burosumab injection) is now publicly funded for eligible adults... The post CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program appeared first on Montreal Gazette.
Outlets covering this story
Montreal Gazette
LEFT
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →